PD-(L)1 x VEGF bispecifics prove a big draw.
ApexOnco Front Page
Recent articles
The company, apparently unbothered by Enhertu, is starting a new HER2 x HER2 phase 3.
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
Adverse events will be closely watched when full data are reported.
Regeneron is facing two FDA decisions for its T-cell engagers.
Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
The company’s BG-C9074 looks competitive, but there are questions about cutoffs and confirmed responses.
The Avanzar study could read out shortly.
